Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study
dc.contributor.author | Perez-Recio, Sandra | |
dc.contributor.author | Pallares, Natalia | |
dc.contributor.author | Grijota-Camino, Maria D. | |
dc.contributor.author | Sanchez-Montalva, Adrian | |
dc.contributor.author | Barcia, Laura | |
dc.contributor.author | Campos-Gutierrez, Silvia | |
dc.contributor.author | Pomar, Virginia | |
dc.contributor.author | Rabunal-Rey, Ramon | |
dc.contributor.author | Balcells, Maria Elvira | |
dc.contributor.author | Gazel, Deniz | |
dc.contributor.author | Montiel, Natalia | |
dc.contributor.author | Vicente, Diego | |
dc.contributor.author | Goic-Barisic, Ivana | |
dc.contributor.author | Schon, Thomas | |
dc.contributor.author | Paues, Jakob | |
dc.contributor.author | Marekovic, Ivana | |
dc.contributor.author | Cacho-Calvo, Juana | |
dc.contributor.author | Barac, Aleksandra | |
dc.contributor.author | Goletti, Delia | |
dc.contributor.author | Garcia-Gasalla, Mercedes | |
dc.contributor.author | Maria Barcala, Jose | |
dc.contributor.author | Teresa Tortola, Maria | |
dc.contributor.author | Anibarro, Luis | |
dc.contributor.author | Suarez-Toste, Isabel | |
dc.contributor.author | Moga, Esther | |
dc.contributor.author | Gude-Gonzalez, Maria J. | |
dc.contributor.author | Naves, Rodrigo | |
dc.contributor.author | Karsligil, Tekin | |
dc.contributor.author | Martin-Penaranda, Tania | |
dc.contributor.author | Stevanovic, Goran | |
dc.contributor.author | Trigo, Matilde | |
dc.contributor.author | Rubio, Veronica | |
dc.contributor.author | Karaoglan, Ilkay | |
dc.contributor.author | Bayram, Nazan | |
dc.contributor.author | Alcaide, Fernando | |
dc.contributor.author | Tebe, Cristian | |
dc.contributor.author | Santin, Miguel | |
dc.date.accessioned | 2025-01-20T22:03:07Z | |
dc.date.available | 2025-01-20T22:03:07Z | |
dc.date.issued | 2021 | |
dc.description.abstract | We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune-mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB2-TB1 value.0.6 IU.ml(-1) was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2>TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB2-TB1 result of >0.6 IU.ml(-1) and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 15.4%, and 17.7% with close, frequent, and sporadic contact had a TB2>TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB2-TB1 difference of.0.6 IU.ml(-1) was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection. | |
dc.description.abstract | IMPORTANCE Contact tuberculosis tracing is essential to identify recently infected people, who therefore merit preventive treatment. However, there are no diagnostic tests that can determine whether the infection is a result of a recent exposure or not. It has been suggested that by using the QuantiFERON-TB gold plus, an interferon gamma (IFN-gamma) release assay, a difference in IFN-gamma production between the two antigen tubes (TB2 minus TB1) of.0.6 IU.ml(-1) could serve as a proxy marker for recent infection. In this large multinational study, infected individuals could not be classified according to the risk of recent exposure based on differences in IFN- g in TB1 and TB2 tubes that were higher than 0.6 IU.ml(-1). QuantiFERON-TB gold plus is not able to distinguish between recent and remotely acquired tuberculosis infection, and it should not be used for that purpose in contact tuberculosis tracing. | |
dc.description.funder | Department of Clinical Sciences of the University of Barcelona | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.1128/Spectrum.00972-21 | |
dc.identifier.issn | 2165-0497 | |
dc.identifier.uri | https://doi.org/10.1128/Spectrum.00972-21 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/94019 | |
dc.identifier.wosid | WOS:000736124700071 | |
dc.issue.numero | 3 | |
dc.language.iso | en | |
dc.revista | Microbiology spectrum | |
dc.rights | acceso restringido | |
dc.subject | QuantiFERON-TB gold plus | |
dc.subject | diagnosis | |
dc.subject | latent tuberculosis infection | |
dc.subject | tuberculosis-specific CD8 T cells | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study | |
dc.type | artículo | |
dc.volumen | 9 | |
sipa.index | WOS | |
sipa.trazabilidad | WOS;2025-01-12 |